New hope for tough blood cancers: first human trial launches

NCT ID NCT06651229

First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 21 times

Summary

This early-phase study tests a new drug, JNJ-90189892, in people with acute myeloid leukemia or myelodysplastic neoplasms that returned or didn't respond to treatment. The main goal is to find a safe dose and check for side effects. About 155 adults will take part, and later parts will test the drug combined with other treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinica Univ. de Navarra

    RECRUITING

    Pamplona, 31008, Spain

  • Concord Hospital

    RECRUITING

    Concord, 2139, Australia

  • Hosp Univ Fund Jimenez Diaz

    RECRUITING

    Madrid, 28040, Spain

  • Hospital Universitario Virgen Rocio

    RECRUITING

    Seville, 41013, Spain

  • Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre

    RECRUITING

    Strasbourg, 67200, France

  • Institut Claudius Regaud

    RECRUITING

    Toulouse, 31100, France

  • Institut Paoli-Calmettes

    RECRUITING

    Marseille, 13273, France

  • Peter MacCallum Cancer Centre

    RECRUITING

    Melbourne, 3000, Australia

  • Sir Charles Gairdner Hospital

    RECRUITING

    Nedlands, 6009, Australia

Conditions

Explore the condition pages connected to this study.